Q3 FY26 results and equity infusion of Rs 25.5 crore in Prigiv subsidiary approved

Related Party TransactionsResults View source PDF Explain this filing

PRIVISCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹2754.90

prior close

₹2700.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-2.1% vs market

Specialty Chemicals peers, median of 87sector+0.4%-1.4% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+1.2

15m

+1.3

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+1.0-2.1+0.4-1.4

Next day

-0.0+0.5-0.5+0.4-0.4

+1.7-0.0+1.7-0.3+2.0

-1.3-1.5+0.2-2.1+0.8

+2.0-2.2+4.2-3.4+5.4

+3.1-1.2+4.3-3.1+6.2

+5.2-2.4+7.5-3.3+8.4

15d

+3.7-8.8+12.6-11.3+15.1

+6.6-8.3+14.9-9.9+16.5

+5.3-3.5+8.8-5.8+11.1

+26.4+6.4+20.0+3.8+22.6

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 87Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Privi Speciality Chemicals reported Q3 and 9M FY26 results ended December 2025. Auditors BSR and Co LLP gave an unmodified review. The Board approved an equity investment of Rs 25.5 crore in subsidiary Prigiv Specialties Private Limited, a 51:49 joint venture with Givaudan SA, part of a Rs 50 crore total infusion to fund growth. This qualifies as a related party transaction given promoter directors sit on Prigiv board. An extra Rs 364.23 lakh provision was booked for new labour codes.

Likely market impact

Positive: capital infusion with Givaudan JV supports growth. Steady results with unmodified audit. Related party nature flagged.